Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) was the recipient of a large decrease in short interest in April. As of April 30th, there was short interest totalling 4,610,838 shares, a decrease of 14.4% from the April 15th total of 5,388,329 shares. Approximately 3.9% of the shares of the company are short sold. Based on an average trading volume of 853,319 shares, the short-interest ratio is currently 5.4 days.

Several equities analysts have commented on MTNB shares. Zacks Investment Research raised Matinas BioPharma from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a report on Tuesday, April 16th. Roth Capital started coverage on Matinas BioPharma in a report on Monday, February 11th. They issued a “buy” rating and a $4.75 price target for the company. BTIG Research started coverage on Matinas BioPharma in a report on Friday, May 17th. They issued a “buy” rating and a $5.00 price target for the company. Finally, Maxim Group reaffirmed a “buy” rating and issued a $5.00 price target on shares of Matinas BioPharma in a report on Thursday, May 16th.

Matinas BioPharma stock opened at $1.00 on Wednesday. Matinas BioPharma has a 12 month low of $0.32 and a 12 month high of $1.50.

Matinas BioPharma (NYSEAMERICAN:MTNB) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.01).

Several institutional investors and hedge funds have recently modified their holdings of MTNB. Renaissance Technologies LLC raised its holdings in shares of Matinas BioPharma by 325.6% in the 3rd quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock worth $124,000 after buying an additional 103,200 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Matinas BioPharma in the 4th quarter worth approximately $39,000. IFP Advisors Inc raised its holdings in shares of Matinas BioPharma by 222.0% in the 4th quarter. IFP Advisors Inc now owns 1,775,000 shares of the company’s stock worth $1,083,000 after buying an additional 1,223,828 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Matinas BioPharma by 147.1% in the 4th quarter. BlackRock Inc. now owns 290,589 shares of the company’s stock worth $173,000 after buying an additional 173,005 shares in the last quarter. Finally, Private Advisor Group LLC raised its holdings in shares of Matinas BioPharma by 100.4% in the 4th quarter. Private Advisor Group LLC now owns 49,850 shares of the company’s stock worth $30,000 after buying an additional 24,978 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: “Matinas BioPharma Holdings Inc (MTNB) Short Interest Update” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2019/05/22/matinas-biopharma-holdings-inc-mtnb-short-interest-update.html.

Matinas BioPharma Company Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

Further Reading: How much can an individual set aside as a catch-up contribution?

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.